Join us at Curecast
On November 6, Katie Couric, leading experts, and advocates will share how Project Cure CRC is transforming research and advancing care.
Young-onset colorectal cancer has unique challenges, even after treatment has completed. You're ready to move on with your life. Below are resources for continued success — and for giving back.
Young-onset colorectal cancer patients and survivors face unique challenges. The Alliance’s Never Too Young (N2Y) Program, with the support of a dedicated Taskforce, is changing how the world sees this disease.
Now that you have completed your treatment, you and your care team should discuss your follow-up care plan. The plan will include ongoing monitoring for cancer recurrence and should also address lifestyle and emotional needs.
Clinical trials test cutting-edge approaches for treating, diagnosing, or preventing colorectal cancer. Be a part of research while being proactive as a young-onset survivor.
Most people don't know that colorectal cancer is the second deadliest cancer in the United States or that it's highly preventable — and that’s why we’re turning up the volume on this disease.
Our Helpline is free and available to support you. Helpline staff members are certified patient & family support navigators who have walked in your shoes
Are you ready to take action? Make the mission to end colorectal cancer your own. The Colorectal Cancer Alliance empowers a nation of allies to participate, fundraise, and volunteer.

The Colorectal Cancer Alliance’s 2025 Blue Hope Bash in Washington, D.C., raised $2.1 million for colorectal cancer awareness, research, and patient support.

In this Q&A, get to know Greg Schwem, a passionate and dedicated Colorectal Cancer Alliance volunteer from Illinois, and sign up to be a volunteer yourself!

After losing their sister Meredith to colorectal cancer, Kathryn and Abigail are turning grief into advocacy. Their powerful story highlights the urgent need for CRC awareness and action — especially among young adults who are facing rising rates of this disease.